RxDoctor Payments Data

Agodichi Nwosu, MD

Cardiovascular Disease · Fayetteville, NCNPI 1902942931

Payments from drug & device makers

$15,347in general payments, 2019–2025

Across 178 payments — averaging $86.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$12K
  • Novartis$566
  • Abbott$485
  • Johnson & Johnson$347
  • Pfizer$262
  • Boehringer Ingelheim$236
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,51323%
  • Other$11,83377%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,347 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$169,592
Medicare patients
309
Services billed
2,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$109,016
EntrestoSacubitril/Valsartan57$61,627
XareltoRivaroxaban65$56,252
OzempicSemaglutide47$54,405
BrilintaTicagrelor19$8,914
JanuviaSitagliptin Phosphate13$7,470
Ranolazine ErRanolazine19$2,049
Amlodipine Besylate282$2,029
Atorvastatin Calcium175$2,012
Clonidine15$1,975
ClopidogrelClopidogrel Bisulfate156$1,856
Valsartan50$1,139
Carvedilol119$1,126
Losartan Potassium134$1,099
Labetalol Hcl34$990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$262$109,01691 claims
NovartisEntresto$566$61,62757 claims
Johnson & JohnsonXarelto$347$56,25265 claims
Novo NordiskOzempic$70$54,40547 claims
AstraZenecaBrilinta$232$8,91419 claims
MerckJanuvia$16$7,47013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →